Subscribe to receive our Floor Reports covering all the action on the Texas House and Senate floor!
No significant fiscal implication to the State is anticipated.
No fiscal implication to units of local government is anticipated.
The bill would authorize terminally ill patients or patients with severe chronic diseases, who have exhausted all viable treatment options, to access experimental drugs that have not yet been approved by the United States Food and Drug Administration (FDA). The bill specifically refers to drugs that have passed the first phase (safety phase) but have not passed the second phase (efficacy test) of the FDA drug approval process.
The executive commissioner would be required to adopt rules specifying treatments patients could access. The executive commissioner would have the authorization to approve for treatment experimental drugs that have completed or are in the appropriate phase of a clinical trial in another country.The bill would specifically exclude the use of cannabis to treat patients with terminal illnesses or severe chronic diseases. The bill would allow a manufacturer to charge a patient a fee; and it would authorize, not mandate, a health benefit plan to provide coverage for the cost of an experimental drug.